LoginSignup
COL

Collegium Pharm

Stock
Stock
ISIN: US19459J1043
Ticker: COLL
US19459J1043
COLL

Price

Price

Frequently asked questions

What is Collegium Pharm's market capitalization?

The market capitalization of Collegium Pharm is $980.73M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is Collegium Pharm's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for Collegium Pharm is 15.21. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for Collegium Pharm?

Collegium Pharm's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $2.00. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Collegium Pharm's stock?

Currently, 6 analysts cover Collegium Pharm's stock, with a consensus target price of $41.00. Analyst ratings provide insights into the stock's expected performance.

What is Collegium Pharm's revenue over the trailing twelve months?

Over the trailing twelve months, Collegium Pharm reported a revenue of $599.25M.

What is the EBITDA for Collegium Pharm?

Collegium Pharm's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $361.47M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Collegium Pharm?

Collegium Pharm has a free cash flow of $192.43M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Collegium Pharm's stock?

The 5-year beta for Collegium Pharm is 0.81. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Collegium Pharm have, and what sector and industry does it belong to?

Collegium Pharm employs approximately 197 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Collegium Pharm's shares?

The free float of Collegium Pharm is 31.72M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $980.73M

5Y beta

 0.81

EPS (TTM)

 $2.00

Free Float

 31.72M

P/E ratio (TTM)

 15.21

Revenue (TTM)

 $599.25M

EBITDA (TTM)

 $361.47M

Free Cashflow (TTM)

 $192.43M

Pricing

1D span
$30.41$30.57
52W span
$25.16$42.29

Analyst Ratings

The price target is $41.00 and the stock is covered by 6 analysts.

Buy

3

Hold

3

Sell

0

Information

Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients. Its portfolio also includes Jornay PM.

197

Biotechnology & Drugs

Health Care

Identifier

ISIN

US19459J1043

Primary Ticker

COLL

Knockouts

Join the conversation
Sign upLogin